Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone

NCT07328230 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences, Fuwai Hospital as lead sponsor.

NCT NCT07328230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07328230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
August 1, 2022
Completion date
December 31, 2025
Enrollment
172 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hyperaldosteronism, idiopathic hyperaldosteronism